Teclistamab
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
What will happen during the trial?
This is a two-arm, non-randomized, multicenter, prospective study in adult patients with RRMM, who are administered Teclistamab (TECVAYLI™) or Talquetamab (TALVEY™), in the post-marketing setting.
This study will investigate the use of prophylactic tocilizumab to reduce the incidence and severity of CRS associated with teclistamab administration, to enable administration of the step-up dosing regimen of teclistamab in an outpatient setting.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 75 patients (estimated)
- Sponsors
- Sarah Cannon Research Institute
- Collaborators
- Johnson & Johnson
- Tags
- Bispecific Antibody, B-Cell Maturation Antigen (BCMA), CD3
- Trial Type
- Treatment
- Last Update
- 2 months ago
- SparkCures ID
- 1746
- NCT Identifier
- NCT05972135
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.